2014
DOI: 10.1371/journal.pone.0112148
|View full text |Cite
|
Sign up to set email alerts
|

PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases

Abstract: Currently, there is no efficient therapy for patients with peripheral T cell lymphoma (PTCL). The Proviral Integration site of Moloney murine leukemia virus (PIM) kinases are important mediators of cell survival. We aimed to determine the therapeutic value of PIM kinases because they are overexpressed in PTCL patients, T cell lines and primary tumoral T cells. PIM kinases were inhibited genetically (using small interfering and short hairpin RNAs) and pharmacologically (mainly with the pan-PIM inhibitor (PIMi) … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
13
0

Year Published

2015
2015
2022
2022

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 20 publications
(14 citation statements)
references
References 45 publications
(91 reference statements)
1
13
0
Order By: Relevance
“…The likely existence of compensatory mechanisms among the three isoforms of Pim kinase, Pim-1, Pim-2 and Pim-3, supports the utility of developing pan-Pim kinase inhibitors [36]. Four Pim kinase inhibitors have entered clinical trials to date.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The likely existence of compensatory mechanisms among the three isoforms of Pim kinase, Pim-1, Pim-2 and Pim-3, supports the utility of developing pan-Pim kinase inhibitors [36]. Four Pim kinase inhibitors have entered clinical trials to date.…”
Section: Discussionmentioning
confidence: 99%
“…Doxorubicin-induced DNA damage was significantly increased in lymphoma cell lines exposed to a Pim kinase inhibitor, in association with significant downregulation of the DNA DSB response proteins H2AX, ATM and Chk2 [57]. Similarly, inhibition of Pim kinase in T-cell lymphoma cells downregulated genes involved in DNA repair, including XRCC2 (HR) , XRCC5 (encoding Ku80, in the NHEJ pathway), and ERCC8 (nucleotide excision repair) [36]. Pim kinase inhibition was also found to potentiate paclitaxel-induced apoptosis through decreased repair via the NHEJ pathway, with inhibition of ATM, DNA-PKcs and Ku activity and/or expression [58].…”
Section: Discussionmentioning
confidence: 99%
“…For instance, PIM2 phosphorylates and inhibits the pro-apoptotic protein Bcl-2-associated death promoter (BAD) and also targets the eukaryotic translation initiation factor 4B (eIF4B) [4]. Accordingly, pharmacological PIM inhibition induces apoptosis and/or suppresses the proliferation of peripheral T cell lymphoma cells [5], chronic lymphocytic leukemia cells [6], and myeloid leukemia cells [79]. In addition to hematopoietic malignancies, PIM kinases are also overexpressed in a variety of solid tumors, including prostate and pancreatic cancer, gastric, colorectal and liver carcinomas, squamous cell carcinoma and bladder cancer [2].…”
Section: Introductionmentioning
confidence: 99%
“…PIM1 decreases sensitivity to ALK TKIs in ALK-positive ALCL. Given that a strong synergistic effect was previously shown on simultaneous inhibition of ALK and PIM kinases in ALK-positive ALCL cell lines 46 , PIM1 was overexpressed and sensitivity to ALK inhibitors monitored in ALK-positive ALCL cell lines. Karpas 299 and SU-DHL-1 cells were transduced to express components of the CRISPR SAM complex whose activity was confirmed (Supplementary Fig.…”
Section: Resultsmentioning
confidence: 96%